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Abstract
Since detection of hepatitis C virus RNA by the polymerase chain reaction (PCR) showed that
there existed anti-C100-3 (anti-HCV) antibody negative patients infected with HCV, we attempted
to find out whether there were any clinical or viral genomic differences between the anti-HCV anti-
body positive and negative groups. One hundred and fifty-nine patients with chronic liver diseases
with hepatitis C virus RNA in their sera were selected. Anti-HCV antibody was tested for anti-
C100-3 antibody by an enzyme linked immunosorbent assay. The incidence of anti-HCV antibody
was 129/159. The concentration of serum gamma-globulin, the titier of ZTT, and the positive rate
of the PCR with the primers of the NS3/4 region (NS3/4PCR) were significantly higher in the anti-
HCV antibody positive group than in the negative group. However, the other data such as alanine
aminotransferase activity or past history were not significantly different. Nucleotide sequence of
the cDNA fragments of NS3/4 region amplified by the PCR did not differ significantly between
isolates from anti-HCV antibody positive and negative sera. The sequences observed in the present
study did not differ significantly from those reported previously. Although there remains the pos-
sibility that the variation of viral genomic sequences may cause the absence of anti-HCV antibody,
these results suggested that the individual clinical backgrounds or immunoreactivity of the patients
might influence the antibody development.
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